

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on the date shown below:

February 27, 2003
David Saliwanchik

David R. Saliwanchik, Patent Attorney

INFORMATION DISCLOSURE STATEMENT
Examining Group 1614
Patent Application
Docket No. BPD-103
Serial No. 10/071,509

1614
RECEIVED
MAR 05 2003
TECH CENTER 1600/2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : unknown
Art Unit : 1614
Applicant(s) : Alfred Fahr, Rolf Muller
Serial No. : 10/071,509
Filed : February 8, 2002
Conf. No. : 3436
For : Invasomes for Therapy of Disorders, their Production and Use

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 AND 1.98

Sir:


In accordance with 37 C.F.R. § 1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed.

Please note that we are in the process of obtaining a translation of German Patent No. 199 40 227 and will furnish a copy of this document to the PTO as soon as possible.

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO/SB/08 with initials or other appropriate marks.

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



David R. Saliwanchik

Patent Attorney

Registration No. 31,794

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: 2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

DRS/dkt

Attachments: Form PTO/SB/08 (4 pages)
Copies of cited references



RECEIVED

MAR 05 2003

TECH CENTER 1009/2900+

Approved for use through 10/31/2002 / OMB 0634-0047
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/071,509
Filing Date	February 8, 2002
First Named Inventor	Alfred Fahr
Art Unit	1614
Examiner Name	unknown
Attorney Docket Number	BPD-103

Sheet 1 of 4

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U1	US-5,993,851	11/30/1999	Foldvari	
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			
	U10	US-			
	U11	US-			
	U12	US-			
	U13	US-			
	U14	US-			
	U15	US-			
	U16	US-			
	U17	US-			
	U18	US-			
	U19	US-			
	U20	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1	WO 92/03122 A1 (Abstract)	03/05/1992	Cevc		
	F2	WO 99/40932 A1	08/19/1999	Modi		
	F3	WO 01/13887 A2 (Abstract)	03/01/2001	Merckle GmbH		
	F4	DE 199 40 227 A1	03/08/2001	Merckle GmbH		
	F5	GB 2 326 337 A	12/23/1998	Phares Pharmaceutical Research NV		
	F6					
	F7					
	F8					
	F9					
	F10					

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED

MAR 05 2003

TECH CENTER 1601/2900+

Approved for use through 10/31/2002 (OMB 0551-0041)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Complete if Known

Application Number	10/071,509
Filing Date	February 8, 2002
First Named Inventor	Alfred Fahr
Group Art Unit	1614
Examiner Name	unknown
Attorney Docket Number	BPD-103

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	ABRAMS, J. R., et al., "CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris," <i>Journal of Clinical Investigation</i> , May 1999, pp. 1243-1252, Vol. 103, No. 9.	
	R2	AGRAWAL, S. and ZHAO, Q., "Antisense therapeutics," <i>Current Opinion in Chemical Biology</i> , August 1998, pp. 519-528, Vol. 2, No. 4.	
	R3	BAADSGAARD, O., "Alopecia areata: an immunologic disease?" <i>Journal of Investigative Dermatology</i> , May 1991, pp. 89S-90S, Vol. 96, No. 5.	
	R4	BLACK, K.S., et al., "Site-specific suppression of cell-mediated immunity by cyclosporine," <i>Journal of Investigative Dermatology</i> , May 1990, pp. 644-648, Vol. 94, No. 5.	
	R5	COLLAZO, C., and GALÁN, J., "The invasion-associated type-III protein secretion system in <i>Salmonella</i> - a review", <i>Gene</i> (1997), 192:51-59; Elsevier Science B.V.	
	R6	CARTHEW, R. W., "Gene silencing by double-stranded RNA," <i>Current Opinion in Cell Biology</i> , April 2001, pp. 244-248, Vol. 13, No. 2.	
	R7	CASEY, B. P. and GLAZER, P. M., "Gene targeting via triple-helix formation," <i>Progress in Nucleic Acid Research and Molecular Biology</i> , 2001, pp. 163-192, Vol. 67.	
	R8	CEVC, G., et al., <i>Advanced Drug Delivery Reviews</i> , 1996, pp. 349-378, Vol. 18.	
	R9	DE BOER, M. L., et al., "Role of nuclear factor of activated T cells (NFAT) in the expression of interleukin-5 and other cytokines involved in the regulation of hemopoietic cells," <i>International Journal of Biochemistry & Cell Biology</i> , 1999, pp. 1221-1236, Vol. 31, No. 10.	
	R10	ECONOMIDOU, J., et al., "Effects of cyclosporin A on immune activation markers in patients with active psoriasis," <i>Dermatology</i> , 1999, pp. 144-148, Vol. 199, No. 2.	
	R11	ELBASHIR, S. M., et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," <i>Nature</i> , May 24, 2001, pp. 494-498, Vol. 411, No. 6836.	
	R12	ELLMEIER, W., et al., "The regulation of CD4 and CD8 coreceptor gene expression during T cell development," <i>Annual Review of Immunology</i> , 1999, pp. 523-554, Vol. 17.	
	R13	FERRANDO, J. and GRIMALT, R., "Partial response of severe alopecia areata to cyclosporine A," <i>Dermatology</i> , 1999, pp. 67-69, Vol. 199, No. 1.	


Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED

MAR 05 2003

TECH CENTER 1800/2000

Approved for use through 10/31/2002. U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 4

Complete if Known

Application Number	10/071,509
Filing Date	February 8, 2002
First Named Inventor	Alfred Fahr
Group Art Unit	1614
Examiner Name	unknown
Attorney Docket Number	BPD-103

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R14	GILHAR, A., <i>et al.</i> , "Topical cyclosporin A in alopecia areata," <i>Acta dermato-venereologica</i> , 1989, pp. 252-253, Vol. 69, No. 3.	
	R15	GOLLNICK and ORFANOS, C. F. Orfanos, and R. Happle, eds., <i>Hair and Hair Diseases</i> , 1990, pp. 529-569, Springer-Verlag, Berlin.	
	R16	GOSSEN, M., <i>et al.</i> , "Inducible gene expression systems for higher eukaryotic cells," <i>Current Opinion in Biotechnology</i> , October 1994, pp. 516-520, Vol. 5, No. 5.	
	R17	GRIFFITHS, C. E., <i>et al.</i> , "Topical cyclosporin and psoriasis," <i>Lancet</i> , April 4, 1987, p. 806, Vol 1, No. 8536.	
	R18	GUO, J., <i>et al.</i> , "Lecithin vesicular carriers for transdermal delivery of cyclosporin A," <i>International Journal of Pharmaceutics</i> , January 25, 2000, pp. 201-207, Vol. 194, No. 2.	
	R19	HAMM, H., <i>et al.</i> , "HLA-DR and HLA-DQ antigen expression of anagen and telogen hair bulbs in long-standing alopecia areata," <i>Archives for Dermatological Research</i> , 1988, pp. 179-181, Vol. 280, No. 3.	
	R20	HERMANN, R., <i>et al.</i> , "Topical Ciclosporin for Psoriasis: In vitro Skin Penetration and Clinical Study", <i>Skin Pharmacol.</i> , 1981, 1:246-249; Karger AG, Basel, Switzerland	
	R21	HOOIJBERG, E., <i>et al.</i> , "NFAT-controlled expression of GFP permits visualization and isolation of antigen-stimulated primary human T cells," <i>Blood</i> , July 15, 2000, pp. 459-466, Vol. 96, No. 2.	
	R22	HORN, D., and RIEGER, J., "Organic Nanoparticles in the Aqueous Phase—Theory, Experiment, and Use", <i>Angew. Chem., Int. Ed.</i> , 2001, 40:4330-4361; Wiley-VCH Verlag GmbH, Germany	
	R23	LEE, <i>et al.</i> , <i>Nature</i> , 1981, pp. 228-232, Vol. 214.	
	R24	MCELWEE, K. J., <i>et al.</i> , "Partial restoration of hair growth in the DEBR model for Alopecia areata after in vivo depletion of CD4+ T cells," <i>British Journal of Dermatology</i> , March 1999, pp. 432-437, Vol. 140, No. 3.	
	R25	MEZEI M. and GULASEKHARAM V., "Liposomes—a selective drug delivery system for the topical route of administration: Lotion dosage form.," <i>Life Sciences</i> , May 5, 1980, pp. 1473-1477, Vol. 26, No. 18.	
	R26	MICHEL, <i>et al.</i> , "Effect of Liposomes on Percutaneous Penetration of Lipophilic Materials", <i>International Journal of Pharmaceutics</i> , 1992, pp. 93-105, Vol. 84.	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED
MAR 05 2003
TECH CENTER 1600/2900
PTO/SB/08B (10-01)
OMB 0651-0031

Approved for use through 10/31/2002. U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known		
				Application Number	10/071,509	
Sheet		4	of	4	Filing Date	February 8, 2002
					First Named Inventor	Alfred Fahr
					Group Art Unit	1614
					Examiner Name	unknown
					Attorney Docket Number	BPD-103

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R27	NAEYAERT, J. M., et al., "Cyclosporin in atopic dermatitis: review of the literature and outline of a Belgian consensus," <i>Dermatology</i> , 1999, pp. 145-152, Vol. 198, No. 2.	
	R28	NICKOLOFF, B. J., GRIFFITHS, C. E., "Aberrant intercellular adhesion molecule-1 (ICAM-1) expression by hair-follicle epithelial cells and endothelial leukocyte adhesion molecule-1 (ELAM-1) by vascular cells are important adhesion-molecule alterations in alopecia areata," <i>J. Invest. Dermatol.</i> , May 1991, pp. 91S-92S, Vol. 96, No. 5.	
	R29	NIEMIEC, S.M., et al., "Influence of nonionic liposomal composition on topical delivery of peptide drugs into pilosebaceous units: an in vivo study using the hamster ear model," <i>Pharmaceutical Research</i> , August 1995, pp. 1184-1188, Vol. 12, No. 8.	
	R30	PERRET, C., et al., "Immunohistochemical analysis of T-cell subsets in the peribulbar and intrabulbar infiltrates of alopecia areata," <i>Acta dermato-venereologica</i> , 1984, pp. 26-30, Vol. 64, No. 1.	
	R31	SAFAVI, K. H., et al., "Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989," <i>Mayo Clinic Proceedings</i> , July 1995, pp. 628-633, Vol. 70, No. 7.	
	R32	SUNDBERG, et al., <i>Journal of Investigative Dermatology</i> , 1995, pp. 32-33, Vol. 104.	
	R33	TOBIN, D. J., et al., "Autoantibodies to hair follicles in C3H/HeJ mice with alopecia areata-like hair loss," <i>Journal of Investigative Dermatology</i> , September 1997, pp. 329-333, Vol. 109, No. 3.	
	R34	VANLERBERGHE, et al., "The effect of non-ionic surfactant vesicle (noisome) entrapment on the absorption and distribution of methotrexate in mice", <i>J. Pharm. Pharmacol.</i> (1985), 37:237-242	
	R35	WEINER, et al., "Topical Delivery of Liposomally Encapsulated Interferon Evaluated in a Cutaneous Herpes Guinea Pig Model", <i>Antimicrobial Agents and Chemotherapy</i> , 1989, pp. 1217-1221, Vol. 33.	
	R36	WEINER, N., et al., "Topical Application of Liposomally Entrapped Ciclosporin Evaluated by in vitro Diffusion Studies with Human Skin", <i>Skin Pharmacol.</i> 1991, 4:21-28	
	R37	WEINTRAUB, H. M., "Antisense RNA and DNA," <i>Scientific American</i> , January 1990, pp. 40-46, Vol. 262, No. 1.	
	R38		
	R39		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.